The recent approval of listed options on Spot Bitcoin ETFs opens up new opportunities for hedging and speculation in the ...

R&D Expenses: Research and development expenses for the third quarter of 2024 were $1.0 million, compared to $1.9 million for ...

Knorex Ltd. has filed to raise $11.9 million in an IPO of its Class A ordinary shares. Click here to find out why my outlook ...

On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for ...

That organization is shown below as deployed in order of size in Utah, Rest of US, Texas and the Philippines. Certain ...

The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...

The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Hut 8 Q3 2024 Financial Results ...

Sea's novel synthetic molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the central nervous system, "the CNS"Two potent, selective, pre-clinical stage ...

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and ...

Enveric Biosciences ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, ...

TriSalus Life Sciences, Inc. ( NASDAQ: TLSI) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & ...